A number of pharmaceutical substances have ester or amide as functional groups which may undergo hydrolysis in solutions or in aqueous suspension. Hydrolytic reactions involve nucleophilic attack on labile bonds such as lactam, ester, amide, imine and so on, by water on the drug in the solution and it follows first order kinetics[@CIT1][@CIT2]. Literature reveals that hydrolytic degradation is performed in neutral, acidic and alkaline conditions.

Cilostazol, chemically 6-\[4-(1-cyclohexyl-*1H*-tetrazol-5-y1)-butoxy\]-3,4-dihydro-2(*1H*)-- quinolinone ([fig. 1](#F0001){ref-type="fig"}), is a quinolinone derivative that inhibits cellular phosphodiesterase III, and is used for inhibition of platelet aggregation and as a vasodilator [@CIT3]--[@CIT6]. Literature survey reveals that only one chromatographic method is reported for quantitative analysis of cilostazol and its metabolites in human plasma[@CIT7].

![Structure of cilostazol.](IJPhS-70-222-g001){#F0001}

In the present work, RP-HPLC method was developed and validated for quantitative estimation of cilostazol in tablet dosage form and hydrolytic degradation of cilostazol was performed and analysized by validated RP-HPLC method.

Cilostazol working standard was gifted by IPCA laboratories, Ratlam (MP) and solvents acetonitrile and methanol were HPLC grade from Merck Ltd., India. All other chemicals (sodium hydroxide, hydrochloric acid and potassium hydroxide) were analytical grade from Merck Ltd., India. Cilostazol tablets (Pletoz-50, Hetero Drugs Ltd., Hyderabad) were procured from local market.

For the RP-HPLC method development and hydrolytic degradation analysis of cilostazol instrument and separation variables are shown [Table 1](#T0001){ref-type="table"}. Cilostazol shows retention time 5.7±0.1 min in the set of separation variables. Six replicates were injected separately to study system suitability parameters retention time (RT), area under curve (AUC), number of theoretical plates, tailing factors and height equivalent theoretical plates (HETP).

###### 

INSTRUMENTS AND SEPARATION VARIABLES

  Instrument                         Parameters
  ---------------------------------- --------------------------------------------------------------------------
  HPLC system                        
   HPLC pump                         LC-10ATvp Shimadzu
   Column                            Solvent delivery module LC-10ATvp Phenomenex (250 mm × 4.60 mm) Luna 5-4
   Injector                          C18(2),100A
   Detector                          Microliter syringes (Hamilton 702NR) SPD-M10 AVP-Shimadzu, UV/Vis Diode
   Guard column                      Array Detector
   Operation software                Phenoxenex security Guard (universal fit) Class-LC10/M10A
   Filter                            Ufipore N~66~ Nylon 6, 6 membrane (pall life sciences)
  Column                             
   Dimension                         250 mm ×4.60 mm
   Particle size                     5 μm
   Bonded phase                      Octadecylsilane (C18)
  Mobile phase                       
   10 mM phosphate buffer (pH 6.0)   20%
   Acetonitrile                      40%
   Methanol                          40%
  Flow rate                          1.3 ml/min
  Temperature                        Ambient
  Sample size                        20 μl
  Detection wavelength               248 nm
  Retention time                     5.7±0.1 min

Accurately weighed about 100 mg cilostazol was dissolved in 50 ml methanol (HPLC grade) and volume was made upto 100 ml with triple distilled water (stock A, 1000 μg/ml). The stock solution was diluted to obtain 0, 100, 200, 400, 800, 1600 and 3200 ng/ml solution of cilostazol. The dilutions were fillered through 0.45 μm membrane filter and injected. Chromatograms were plotted and repeated for six times. A calibration graph was plotted between the peak AUC vs concentration and regression equation was AUC= 43.45X+156.75 with correlation coefficient r^2^ = 0.9998. The method was validated according to ICH guidelines[@CIT8]. RSD values of all validation parameters are far less than 2% ([Table 2](#T0002){ref-type="table"}).

###### 

VALIDATION PARAMETERS FOR CILOSTAZOL

  Parameters                                  Values
  ------------------------------------------- ----------------------------------------------------------------------------------------
  Linearity                                   100-3200 ng/ml
   Response ratio                             43.63
   SD of RR                                   0.1925
   RSD of RR                                  0.0044
  Range                                       200 - 1200 ng/ml
   SD                                         16.54-37.10
   RSD                                        0.0004 - 0.0023
  Accuracy                                    
   % Mean[\*](#T000F1){ref-type="table-fn"}   100.008
   SD                                         0.065
   RSD                                        0.0006
  Precision                                   
   Repeatability                              
   % Mean[\*](#T000F1){ref-type="table-fn"}   99.99
   SD                                         0.1379
   RSD                                        0.0014
  Intermediate precision                      
   Day to Day                                 
   % Mean[\*](#T000F1){ref-type="table-fn"}   100.03
   SD                                         0.121
   RSD                                        0.0012
  Analyst to analyst                          
   % Mean[\*](#T000F1){ref-type="table-fn"}   100.03
   SD                                         0.175
   RSD                                        0.0017
  Specificity                                 After hydrolytic degradation, peak response was same as previous because it is stable.

\- mean of six replicates, SD - Standard deviation, RSD - Relative standard deviation, RR - Response ratio, ng/ml - nanogram/milliliter

Twenty tablets (Pletoz-50, Hetero Drugs Ltd., Hyderabad) were weighed and finely powdered. Powder equivalent to 100 mg of cilostazol was dissolved in 50 ml methanol (HPLC grade) and volume was made upto 100 ml with triple distilled water. The sample was sonicated for 15 min and filtered through Whatmann paper no. 41 (stock P, 1000 μg/ml). 10 milliliters of this stock was diluted up to 100 ml with 50% aqueous methanol (stock Q, 100 μg/ml) and then further diluted up to 100 ml obtain stock R (10 μg/ml). Aliquots of 10 μg/ml were diluted to obtain concentration of 800 ng/ml and filtered through 0.45 μm membrane filter. Samples were analysed and statistical calculations were carried out ([Table 3](#T0003){ref-type="table"}).

###### 

ANALYSIS OF CILOSTAZOL TABLETS

  Conc. of tablet dilution (ng/ml)   Area under curve   Concentration found (ng/ml)   \% Found
  ---------------------------------- ------------------ ----------------------------- ----------
  800                                35075              803.64                        100.46
  800                                34825              797.89                        99.74
  800                                35120              84.68                         100.59
  800                                35012              802.92                        100.37
  800                                34769              796.60                        99.58
  800                                35150              805.37                        100.67
  Mean                                                                                100.24
  SD                                                                                  0.4600
  RSD                                                                                 0.0046
  SEσ                                                                                 0.1878

ng/ml - nanogram/milliliter, SD - Standard deviation, RSD - Relative standard deviation, SEσ - Standard error of standard deviation

Hydrolytic degradation in alkaline condition was carried out by dissolving accurately weighed 100 mg cilostazol in 50 ml methanol (HPLC grade) and volume was made upto 100 ml with 2 N NaOH. The solution was refluxed on water bath at 60º for 5 h. Aliquot of above solution was neutralized with 1 N HCl and diluted with diluent to obtain 800 ng/ml solutions. The sample solution was analysed and chromatogram was recorded. No degradation of cilostazol was found in 1 N NaOH at 60º after 5 h. Further, cilostazol was degraded in 2 N NaOH and 5 N NaOH and cilostazol was found to be stable.

Hydrolytic degradation under acidic conditions was performed by dissolving 100 mg cilostazol in 50 ml acetonitrile (HPLC grade) and volume was made upto 100 ml with 2 N HCl. The solution was refluxed on water bath at 60º for 5 h. Aliquots of above solution was neutralized with 1 N NaOH and diluted with diluent to obtain 800 ng/ml solutions. The sample solution was analysed and chromatogram was recorded. No degradation of cilostazol was found in 1 N HCl at 60º after 5 h. Further, the solution was degraded in 2 N HCl and 5 N HCl and was found to be stable.

Cilostazol tablets were analysed by validated RP-HPLC method and cilostazol was found in between 99.58-100.67% with relative standard deviation 0.0046. As cilostazol is insoluble in water and sodium hydroxide solution, cosolvent was required to perform alkali degradation of cilostazol. Acetonitrile as cosolvent was avoided for alkali degradation because it produces phase separation with 1 N or more concentrated NaOH solution[@CIT9]. So 50% methanolic sodium hydroxide solution was recommended to perform alkaline degradation of cilostazol. As per decision tree[@CIT10] the degradation of cilostazol was performed in 50% methanolic 1 N, 2 N and 5 N NaOH at 60º for 5 h. Since there was no other peak (except cilostazol at RT 5.7±01 min) after treating by above stress conditions, cilostazol is stable drug under these conditions.

Cilostazol is also insoluble in hydrochloric acid and methanol as cosolvent is avoided with high concentration of HCl due to presence of amide group in cilostazol. Methanol may react with amide group and produce significant experimental artifact components[@CIT9]. The acidic degradation of cilostazol was performed in 50% acetonitrile 1 N, 2 N and 5 N HCl at 60º for 5 h and no peaks (except cilostazol at 5.7 ± 0.1 min) were seen after treating by above stress conditions. Thus, cilostazol is also stable in 50% acetonitrile HCl.
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